US SB148 | 2023-2024 | 118th Congress
Status
Spectrum: Slight Partisan Bill (Democrat 6-3)
Status: Introduced on January 30 2023 - 25% progression, died in chamber
Action: 2023-03-01 - Placed on Senate Legislative Calendar under General Orders. Calendar No. 21.
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on January 30 2023 - 25% progression, died in chamber
Action: 2023-03-01 - Placed on Senate Legislative Calendar under General Orders. Calendar No. 21.
Text: Latest bill text (Introduced) [PDF]
Summary
A bill to enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, and for other purposes.
Title
Stop STALLING Act Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act
Sponsors
| Sen. Amy Klobuchar [D-MN] | Sen. Chuck Grassley [R-IA] | Sen. Richard Durbin [D-IL] | Sen. Mike Braun [R-IN] |
| Sen. Richard Blumenthal [D-CT] | Sen. Ted Cruz [R-TX] | Sen. Cory Booker [D-NJ] | Sen. Jon Ossoff [D-GA] |
| Sen. Peter Welch [D-VT] |
History
| Date | Chamber | Action |
|---|---|---|
| 2023-03-01 | Senate | Placed on Senate Legislative Calendar under General Orders. Calendar No. 21. |
| 2023-03-01 | Senate | Committee on the Judiciary. Reported by Senator Durbin with an amendment in the nature of a substitute. Without written report. |
| 2023-02-09 | Senate | Committee on the Judiciary. Ordered to be reported with an amendment in the nature of a substitute favorably. |
| 2023-01-30 | Senate | Read twice and referred to the Committee on the Judiciary. |
